secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001193125-25-139959
Event type: debt
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica amends credit agreement, waives going concern covenant through Dec 2025
-------------------------------------------------------------------------------

- Sixth amendment waives Section 7.1(b) and 7.1(c) going concern qualifications for Q2'25, Q3'25, and FY2025 financial statements.
- Company paid amendment fee of $110,465.12 to lenders (OrbiMed Royalty & Credit Opportunities IV, LP).
- Original credit agreement dated July 26, 2023; all other terms unchanged.
- Waiver addresses potential default risk from going concern audit language in upcoming filings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525139959/0001193125-25-139959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525139959/d949783d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-139959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer